Astellas Pharma Inc (ALPMY) 16.6650 $ALPMY Sanofi's Bid

New Post Public Reply Private Reply Replies (0) Message Board

Jul 31, 2016 at 9:17 PM

Astellas Pharma Inc (ALPMY) 16.6650 $ALPMY

Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation . Sanofi's purchase price is...
MDVN: 63.99 (+1.50), JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), SNY: 42.63 (+0.03), NVS: 83.26 (+1.18)

J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 63.99 (+1.50), JNJ: 125.23 (+0.77)

Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 63.99 (+1.50), AZN: 34.14 (-0.15), AMAG: 26.53 (-0.06)

Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 63.99 (+1.50), VRX: 22.30 (-0.83)

Technical Data Influencing the Market - Analyst Notes on CUBA Beverage, Arch Therapeutics, Wolseley and Astellas Pharma
ACCESSWIRE - Wed Mar 09, 6:35AM CST
NEW YORK, NY / ACCESSWIRE / March 9, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CUBA Beverage Co. (OTC: CUBV), Arch Therapeutics Inc. (OTC: ARTH), Wolseley PLC (OTC: WOSYY) and Astellas Pharma Inc. (OTC: ALPMY). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 172.03 (+0.75), ANIK: 49.92 (+0.70), CELG: 112.19 (+0.93)

Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 252.95 (-2.61), IRWD: 14.13 (-0.21), AZN: 34.14 (-0.15)

Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 4.15 (-0.05), HZNP: 19.29 (-0.33), LGND: 134.88 (-0.01)

Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what: Early in the...
OCAT: 8.47 (+0.01)

Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 252.95 (-2.61), IRWD: 14.13 (-0.21), ACHN: 8.28 (+0.01)

Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 67.34 (unch), MYL: 46.79 (+0.07), CORT: 5.80 (-0.06)

Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 82.89 (-0.04), EXEL: 9.18 (+0.23)

Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 25, 9:28AM CST
Image source: Johnson & Johnson. Healthcare conglomerate Johnson & Johnson 's share price may be up only marginally since the week began, but make no mistake about it: The week couldn't have possibly started off better for its long-term...
MDVN: 63.99 (+1.50), JNJ: 125.23 (+0.77), AMGN: 172.03 (+0.75), CELG: 112.19 (+0.93)

Medivation Inc is Down Today -- But Why?
Brian Feroldi, The Motley Fool - Motley Fool - Fri Nov 06, 11:40AM CST
What: Shares of Medivation , biopharmaceutical company primarily focused on treating cancer, were down more than 10% today on heavy volume after the company reported its third quarter results. So what: Revenue during the quarter came in at...
MDVN: 63.99 (+1.50)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...